HSBC Holdings
NPCE icon

HSBC Holdings’s Neuropace NPCE Stock Holding History

HSBC Holdings’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Sell
26,033
-3,715
-12% -$59.8K ﹤0.01% 2367
2026
Q1 		$381K Sell
29,748
-7,899
-21% -$119K ﹤0.01% 2341
2025
Q4 		$579K Sell
37,647
-16,907
-31% -$226K ﹤0.01% 2240
2025
Q3 		$565K Sell
54,554
-4,694
-8% -$44.3K ﹤0.01% 2042
2025
Q2 		$661K Buy
+59,248
New +$741K ﹤0.01% 2003

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

HSBC Holdings's NPCE Position: Q2 2026 in Review

HSBC Holdings reduced its Neuropace (NPCE) stake by 12% in Q2 2026, selling an estimated $59.8K and leaving 26,033 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #2367.

HSBC Holdings first reported a position in NPCE in Q2 2025 and has held it in 5 quarters since. The position peaked at $661K in Q2 2025. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • HSBC Holdings held 26,033 shares of Neuropace worth $420K as of Q2 2026.
  • HSBC Holdings sold 3,715 Neuropace shares in Q2 2026, an estimated $59.8K.
  • Neuropace made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2367 holding.
  • HSBC Holdings first reported a position in Neuropace in Q2 2025 and has held it in 5 quarters since.
  • HSBC Holdings's Neuropace position peaked at $661K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.